Global Nucleotide-based Therapeutics Supply, Demand and Key Producers, 2023-2029
The global Nucleotide-based Therapeutics market size is expected to reach $ 84010 million by 2029, rising at a market growth of 3.6% CAGR during the forecast period (2023-2029).
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
Nucleotide-based therapeutics offer huge potential to specifically modulate cellular pathways in ways not previously possible. These therapies include all nucleic-acid-based approaches that work inside cells to affect gene expression – the genetic blueprint of disease – to ultimately change protein expression and potentially alter the course of disease.
This report studies the global Nucleotide-based Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Nucleotide-based Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nucleotide-based Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Nucleotide-based Therapeutics total market, 2018-2029, (USD Million)
Global Nucleotide-based Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Nucleotide-based Therapeutics total market, key domestic companies and share, (USD Million)
Global Nucleotide-based Therapeutics revenue by player and market share 2018-2023, (USD Million)
Global Nucleotide-based Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)
Global Nucleotide-based Therapeutics total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Nucleotide-based Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Nucleotide-based Therapeutics market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Nucleotide-based Therapeutics Market, By Region:
1. How big is the global Nucleotide-based Therapeutics market?
2. What is the demand of the global Nucleotide-based Therapeutics market?
3. What is the year over year growth of the global Nucleotide-based Therapeutics market?
4. What is the total value of the global Nucleotide-based Therapeutics market?
5. Who are the major players in the global Nucleotide-based Therapeutics market?
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
Nucleotide-based therapeutics offer huge potential to specifically modulate cellular pathways in ways not previously possible. These therapies include all nucleic-acid-based approaches that work inside cells to affect gene expression – the genetic blueprint of disease – to ultimately change protein expression and potentially alter the course of disease.
This report studies the global Nucleotide-based Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Nucleotide-based Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nucleotide-based Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Nucleotide-based Therapeutics total market, 2018-2029, (USD Million)
Global Nucleotide-based Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Nucleotide-based Therapeutics total market, key domestic companies and share, (USD Million)
Global Nucleotide-based Therapeutics revenue by player and market share 2018-2023, (USD Million)
Global Nucleotide-based Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)
Global Nucleotide-based Therapeutics total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Nucleotide-based Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Nucleotide-based Therapeutics market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Nucleotide-based Therapeutics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
- Neuromuscular Diseases
- hATTR
- COVID-19
- Other
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
1. How big is the global Nucleotide-based Therapeutics market?
2. What is the demand of the global Nucleotide-based Therapeutics market?
3. What is the year over year growth of the global Nucleotide-based Therapeutics market?
4. What is the total value of the global Nucleotide-based Therapeutics market?
5. Who are the major players in the global Nucleotide-based Therapeutics market?
1 SUPPLY SUMMARY
1.1 Nucleotide-based Therapeutics Introduction
1.2 World Nucleotide-based Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Nucleotide-based Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Nucleotide-based Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.3 China Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.4 Europe Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.5 Japan Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.6 South Korea Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.7 ASEAN Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.8 India Nucleotide-based Therapeutics Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Nucleotide-based Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Nucleotide-based Therapeutics Major Market Trends
2 DEMAND SUMMARY
2.1 World Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.2 World Nucleotide-based Therapeutics Consumption Value by Region
2.2.1 World Nucleotide-based Therapeutics Consumption Value by Region (2018-2023)
2.2.2 World Nucleotide-based Therapeutics Consumption Value Forecast by Region (2024-2029)
2.3 United States Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.4 China Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.5 Europe Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.6 Japan Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.7 South Korea Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.8 ASEAN Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.9 India Nucleotide-based Therapeutics Consumption Value (2018-2029)
3 WORLD NUCLEOTIDE-BASED THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Nucleotide-based Therapeutics Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Nucleotide-based Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Nucleotide-based Therapeutics in 2022
3.2.3 Global Concentration Ratios (CR8) for Nucleotide-based Therapeutics in 2022
3.3 Nucleotide-based Therapeutics Company Evaluation Quadrant
3.4 Nucleotide-based Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Nucleotide-based Therapeutics Market: Region Footprint
3.4.2 Nucleotide-based Therapeutics Market: Company Product Type Footprint
3.4.3 Nucleotide-based Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Nucleotide-based Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Nucleotide-based Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Nucleotide-based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Nucleotide-based Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Nucleotide-based Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Nucleotide-based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Nucleotide-based Therapeutics Companies and Market Share, 2018-2023
4.3.1 United States Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)
4.4 China Based Companies Nucleotide-based Therapeutics Revenue and Market Share, 2018-2023
4.4.1 China Based Nucleotide-based Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)
4.5 Rest of World Based Nucleotide-based Therapeutics Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Nucleotide-based Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antisense Oligonucleotides (ASO)
5.2.2 siRNA
5.2.3 mRNA
5.3 Market Segment by Type
5.3.1 World Nucleotide-based Therapeutics Market Size by Type (2018-2023)
5.3.2 World Nucleotide-based Therapeutics Market Size by Type (2024-2029)
5.3.3 World Nucleotide-based Therapeutics Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Nucleotide-based Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Neuromuscular Diseases
6.2.2 hATTR
6.2.3 COVID-19
6.2.4 Other
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World Nucleotide-based Therapeutics Market Size by Application (2018-2023)
6.3.2 World Nucleotide-based Therapeutics Market Size by Application (2024-2029)
6.3.3 World Nucleotide-based Therapeutics Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Sarepta Therapeutics
7.1.1 Sarepta Therapeutics Details
7.1.2 Sarepta Therapeutics Major Business
7.1.3 Sarepta Therapeutics Nucleotide-based Therapeutics Product and Services
7.1.4 Sarepta Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Sarepta Therapeutics Recent Developments/Updates
7.1.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
7.2 Ionis Pharmaceuticals
7.2.1 Ionis Pharmaceuticals Details
7.2.2 Ionis Pharmaceuticals Major Business
7.2.3 Ionis Pharmaceuticals Nucleotide-based Therapeutics Product and Services
7.2.4 Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Ionis Pharmaceuticals Recent Developments/Updates
7.2.6 Ionis Pharmaceuticals Competitive Strengths & Weaknesses
7.3 Alnylam
7.3.1 Alnylam Details
7.3.2 Alnylam Major Business
7.3.3 Alnylam Nucleotide-based Therapeutics Product and Services
7.3.4 Alnylam Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Alnylam Recent Developments/Updates
7.3.6 Alnylam Competitive Strengths & Weaknesses
7.4 Biogen
7.4.1 Biogen Details
7.4.2 Biogen Major Business
7.4.3 Biogen Nucleotide-based Therapeutics Product and Services
7.4.4 Biogen Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Biogen Recent Developments/Updates
7.4.6 Biogen Competitive Strengths & Weaknesses
7.5 Nippon Shinyaku
7.5.1 Nippon Shinyaku Details
7.5.2 Nippon Shinyaku Major Business
7.5.3 Nippon Shinyaku Nucleotide-based Therapeutics Product and Services
7.5.4 Nippon Shinyaku Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Nippon Shinyaku Recent Developments/Updates
7.5.6 Nippon Shinyaku Competitive Strengths & Weaknesses
7.6 Sobi
7.6.1 Sobi Details
7.6.2 Sobi Major Business
7.6.3 Sobi Nucleotide-based Therapeutics Product and Services
7.6.4 Sobi Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Sobi Recent Developments/Updates
7.6.6 Sobi Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Nucleotide-based Therapeutics Product and Services
7.7.4 Novartis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 BioNTech
7.8.1 BioNTech Details
7.8.2 BioNTech Major Business
7.8.3 BioNTech Nucleotide-based Therapeutics Product and Services
7.8.4 BioNTech Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 BioNTech Recent Developments/Updates
7.8.6 BioNTech Competitive Strengths & Weaknesses
7.9 Pfizer
7.9.1 Pfizer Details
7.9.2 Pfizer Major Business
7.9.3 Pfizer Nucleotide-based Therapeutics Product and Services
7.9.4 Pfizer Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Recent Developments/Updates
7.9.6 Pfizer Competitive Strengths & Weaknesses
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Details
7.10.2 Moderna Therapeutics Major Business
7.10.3 Moderna Therapeutics Nucleotide-based Therapeutics Product and Services
7.10.4 Moderna Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Moderna Therapeutics Recent Developments/Updates
7.10.6 Moderna Therapeutics Competitive Strengths & Weaknesses
7.11 Jazz Pharmaceuticals
7.11.1 Jazz Pharmaceuticals Details
7.11.2 Jazz Pharmaceuticals Major Business
7.11.3 Jazz Pharmaceuticals Nucleotide-based Therapeutics Product and Services
7.11.4 Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Jazz Pharmaceuticals Recent Developments/Updates
7.11.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
7.12 CureVac
7.12.1 CureVac Details
7.12.2 CureVac Major Business
7.12.3 CureVac Nucleotide-based Therapeutics Product and Services
7.12.4 CureVac Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 CureVac Recent Developments/Updates
7.12.6 CureVac Competitive Strengths & Weaknesses
7.13 Regulus Therapeutics
7.13.1 Regulus Therapeutics Details
7.13.2 Regulus Therapeutics Major Business
7.13.3 Regulus Therapeutics Nucleotide-based Therapeutics Product and Services
7.13.4 Regulus Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Regulus Therapeutics Recent Developments/Updates
7.13.6 Regulus Therapeutics Competitive Strengths & Weaknesses
7.14 ProQR
7.14.1 ProQR Details
7.14.2 ProQR Major Business
7.14.3 ProQR Nucleotide-based Therapeutics Product and Services
7.14.4 ProQR Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 ProQR Recent Developments/Updates
7.14.6 ProQR Competitive Strengths & Weaknesses
7.15 Secarna
7.15.1 Secarna Details
7.15.2 Secarna Major Business
7.15.3 Secarna Nucleotide-based Therapeutics Product and Services
7.15.4 Secarna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Secarna Recent Developments/Updates
7.15.6 Secarna Competitive Strengths & Weaknesses
7.16 MiNA Therapeutics
7.16.1 MiNA Therapeutics Details
7.16.2 MiNA Therapeutics Major Business
7.16.3 MiNA Therapeutics Nucleotide-based Therapeutics Product and Services
7.16.4 MiNA Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 MiNA Therapeutics Recent Developments/Updates
7.16.6 MiNA Therapeutics Competitive Strengths & Weaknesses
7.17 Sylentis
7.17.1 Sylentis Details
7.17.2 Sylentis Major Business
7.17.3 Sylentis Nucleotide-based Therapeutics Product and Services
7.17.4 Sylentis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Sylentis Recent Developments/Updates
7.17.6 Sylentis Competitive Strengths & Weaknesses
7.18 Arrowhead
7.18.1 Arrowhead Details
7.18.2 Arrowhead Major Business
7.18.3 Arrowhead Nucleotide-based Therapeutics Product and Services
7.18.4 Arrowhead Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Arrowhead Recent Developments/Updates
7.18.6 Arrowhead Competitive Strengths & Weaknesses
7.19 Silence Therapeutics
7.19.1 Silence Therapeutics Details
7.19.2 Silence Therapeutics Major Business
7.19.3 Silence Therapeutics Nucleotide-based Therapeutics Product and Services
7.19.4 Silence Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 Silence Therapeutics Recent Developments/Updates
7.19.6 Silence Therapeutics Competitive Strengths & Weaknesses
7.20 Dicerna
7.20.1 Dicerna Details
7.20.2 Dicerna Major Business
7.20.3 Dicerna Nucleotide-based Therapeutics Product and Services
7.20.4 Dicerna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Dicerna Recent Developments/Updates
7.20.6 Dicerna Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Nucleotide-based Therapeutics Industry Chain
8.2 Nucleotide-based Therapeutics Upstream Analysis
8.3 Nucleotide-based Therapeutics Midstream Analysis
8.4 Nucleotide-based Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Nucleotide-based Therapeutics Introduction
1.2 World Nucleotide-based Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Nucleotide-based Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Nucleotide-based Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.3 China Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.4 Europe Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.5 Japan Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.6 South Korea Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.7 ASEAN Nucleotide-based Therapeutics Market Size (2018-2029)
1.3.8 India Nucleotide-based Therapeutics Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Nucleotide-based Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Nucleotide-based Therapeutics Major Market Trends
2 DEMAND SUMMARY
2.1 World Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.2 World Nucleotide-based Therapeutics Consumption Value by Region
2.2.1 World Nucleotide-based Therapeutics Consumption Value by Region (2018-2023)
2.2.2 World Nucleotide-based Therapeutics Consumption Value Forecast by Region (2024-2029)
2.3 United States Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.4 China Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.5 Europe Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.6 Japan Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.7 South Korea Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.8 ASEAN Nucleotide-based Therapeutics Consumption Value (2018-2029)
2.9 India Nucleotide-based Therapeutics Consumption Value (2018-2029)
3 WORLD NUCLEOTIDE-BASED THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Nucleotide-based Therapeutics Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Nucleotide-based Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Nucleotide-based Therapeutics in 2022
3.2.3 Global Concentration Ratios (CR8) for Nucleotide-based Therapeutics in 2022
3.3 Nucleotide-based Therapeutics Company Evaluation Quadrant
3.4 Nucleotide-based Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Nucleotide-based Therapeutics Market: Region Footprint
3.4.2 Nucleotide-based Therapeutics Market: Company Product Type Footprint
3.4.3 Nucleotide-based Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Nucleotide-based Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Nucleotide-based Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Nucleotide-based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Nucleotide-based Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Nucleotide-based Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Nucleotide-based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Nucleotide-based Therapeutics Companies and Market Share, 2018-2023
4.3.1 United States Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)
4.4 China Based Companies Nucleotide-based Therapeutics Revenue and Market Share, 2018-2023
4.4.1 China Based Nucleotide-based Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)
4.5 Rest of World Based Nucleotide-based Therapeutics Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Nucleotide-based Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antisense Oligonucleotides (ASO)
5.2.2 siRNA
5.2.3 mRNA
5.3 Market Segment by Type
5.3.1 World Nucleotide-based Therapeutics Market Size by Type (2018-2023)
5.3.2 World Nucleotide-based Therapeutics Market Size by Type (2024-2029)
5.3.3 World Nucleotide-based Therapeutics Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Nucleotide-based Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Neuromuscular Diseases
6.2.2 hATTR
6.2.3 COVID-19
6.2.4 Other
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World Nucleotide-based Therapeutics Market Size by Application (2018-2023)
6.3.2 World Nucleotide-based Therapeutics Market Size by Application (2024-2029)
6.3.3 World Nucleotide-based Therapeutics Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Sarepta Therapeutics
7.1.1 Sarepta Therapeutics Details
7.1.2 Sarepta Therapeutics Major Business
7.1.3 Sarepta Therapeutics Nucleotide-based Therapeutics Product and Services
7.1.4 Sarepta Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Sarepta Therapeutics Recent Developments/Updates
7.1.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
7.2 Ionis Pharmaceuticals
7.2.1 Ionis Pharmaceuticals Details
7.2.2 Ionis Pharmaceuticals Major Business
7.2.3 Ionis Pharmaceuticals Nucleotide-based Therapeutics Product and Services
7.2.4 Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Ionis Pharmaceuticals Recent Developments/Updates
7.2.6 Ionis Pharmaceuticals Competitive Strengths & Weaknesses
7.3 Alnylam
7.3.1 Alnylam Details
7.3.2 Alnylam Major Business
7.3.3 Alnylam Nucleotide-based Therapeutics Product and Services
7.3.4 Alnylam Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Alnylam Recent Developments/Updates
7.3.6 Alnylam Competitive Strengths & Weaknesses
7.4 Biogen
7.4.1 Biogen Details
7.4.2 Biogen Major Business
7.4.3 Biogen Nucleotide-based Therapeutics Product and Services
7.4.4 Biogen Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Biogen Recent Developments/Updates
7.4.6 Biogen Competitive Strengths & Weaknesses
7.5 Nippon Shinyaku
7.5.1 Nippon Shinyaku Details
7.5.2 Nippon Shinyaku Major Business
7.5.3 Nippon Shinyaku Nucleotide-based Therapeutics Product and Services
7.5.4 Nippon Shinyaku Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Nippon Shinyaku Recent Developments/Updates
7.5.6 Nippon Shinyaku Competitive Strengths & Weaknesses
7.6 Sobi
7.6.1 Sobi Details
7.6.2 Sobi Major Business
7.6.3 Sobi Nucleotide-based Therapeutics Product and Services
7.6.4 Sobi Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Sobi Recent Developments/Updates
7.6.6 Sobi Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Nucleotide-based Therapeutics Product and Services
7.7.4 Novartis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 BioNTech
7.8.1 BioNTech Details
7.8.2 BioNTech Major Business
7.8.3 BioNTech Nucleotide-based Therapeutics Product and Services
7.8.4 BioNTech Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 BioNTech Recent Developments/Updates
7.8.6 BioNTech Competitive Strengths & Weaknesses
7.9 Pfizer
7.9.1 Pfizer Details
7.9.2 Pfizer Major Business
7.9.3 Pfizer Nucleotide-based Therapeutics Product and Services
7.9.4 Pfizer Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Recent Developments/Updates
7.9.6 Pfizer Competitive Strengths & Weaknesses
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Details
7.10.2 Moderna Therapeutics Major Business
7.10.3 Moderna Therapeutics Nucleotide-based Therapeutics Product and Services
7.10.4 Moderna Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Moderna Therapeutics Recent Developments/Updates
7.10.6 Moderna Therapeutics Competitive Strengths & Weaknesses
7.11 Jazz Pharmaceuticals
7.11.1 Jazz Pharmaceuticals Details
7.11.2 Jazz Pharmaceuticals Major Business
7.11.3 Jazz Pharmaceuticals Nucleotide-based Therapeutics Product and Services
7.11.4 Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Jazz Pharmaceuticals Recent Developments/Updates
7.11.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
7.12 CureVac
7.12.1 CureVac Details
7.12.2 CureVac Major Business
7.12.3 CureVac Nucleotide-based Therapeutics Product and Services
7.12.4 CureVac Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 CureVac Recent Developments/Updates
7.12.6 CureVac Competitive Strengths & Weaknesses
7.13 Regulus Therapeutics
7.13.1 Regulus Therapeutics Details
7.13.2 Regulus Therapeutics Major Business
7.13.3 Regulus Therapeutics Nucleotide-based Therapeutics Product and Services
7.13.4 Regulus Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Regulus Therapeutics Recent Developments/Updates
7.13.6 Regulus Therapeutics Competitive Strengths & Weaknesses
7.14 ProQR
7.14.1 ProQR Details
7.14.2 ProQR Major Business
7.14.3 ProQR Nucleotide-based Therapeutics Product and Services
7.14.4 ProQR Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 ProQR Recent Developments/Updates
7.14.6 ProQR Competitive Strengths & Weaknesses
7.15 Secarna
7.15.1 Secarna Details
7.15.2 Secarna Major Business
7.15.3 Secarna Nucleotide-based Therapeutics Product and Services
7.15.4 Secarna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Secarna Recent Developments/Updates
7.15.6 Secarna Competitive Strengths & Weaknesses
7.16 MiNA Therapeutics
7.16.1 MiNA Therapeutics Details
7.16.2 MiNA Therapeutics Major Business
7.16.3 MiNA Therapeutics Nucleotide-based Therapeutics Product and Services
7.16.4 MiNA Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 MiNA Therapeutics Recent Developments/Updates
7.16.6 MiNA Therapeutics Competitive Strengths & Weaknesses
7.17 Sylentis
7.17.1 Sylentis Details
7.17.2 Sylentis Major Business
7.17.3 Sylentis Nucleotide-based Therapeutics Product and Services
7.17.4 Sylentis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Sylentis Recent Developments/Updates
7.17.6 Sylentis Competitive Strengths & Weaknesses
7.18 Arrowhead
7.18.1 Arrowhead Details
7.18.2 Arrowhead Major Business
7.18.3 Arrowhead Nucleotide-based Therapeutics Product and Services
7.18.4 Arrowhead Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Arrowhead Recent Developments/Updates
7.18.6 Arrowhead Competitive Strengths & Weaknesses
7.19 Silence Therapeutics
7.19.1 Silence Therapeutics Details
7.19.2 Silence Therapeutics Major Business
7.19.3 Silence Therapeutics Nucleotide-based Therapeutics Product and Services
7.19.4 Silence Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 Silence Therapeutics Recent Developments/Updates
7.19.6 Silence Therapeutics Competitive Strengths & Weaknesses
7.20 Dicerna
7.20.1 Dicerna Details
7.20.2 Dicerna Major Business
7.20.3 Dicerna Nucleotide-based Therapeutics Product and Services
7.20.4 Dicerna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Dicerna Recent Developments/Updates
7.20.6 Dicerna Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Nucleotide-based Therapeutics Industry Chain
8.2 Nucleotide-based Therapeutics Upstream Analysis
8.3 Nucleotide-based Therapeutics Midstream Analysis
8.4 Nucleotide-based Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Nucleotide-based Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Nucleotide-based Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Nucleotide-based Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Nucleotide-based Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Nucleotide-based Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Nucleotide-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Nucleotide-based Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Nucleotide-based Therapeutics Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Nucleotide-based Therapeutics Players in 2022
Table 12. World Nucleotide-based Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Nucleotide-based Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Nucleotide-based Therapeutics Player
Table 15. Nucleotide-based Therapeutics Market: Company Product Type Footprint
Table 16. Nucleotide-based Therapeutics Market: Company Product Application Footprint
Table 17. Nucleotide-based Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Nucleotide-based Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Nucleotide-based Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)
Table 23. China Based Nucleotide-based Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)
Table 26. Rest of World Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)
Table 29. World Nucleotide-based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Nucleotide-based Therapeutics Market Size by Type (2018-2023) & (USD Million)
Table 31. World Nucleotide-based Therapeutics Market Size by Type (2024-2029) & (USD Million)
Table 32. World Nucleotide-based Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Nucleotide-based Therapeutics Market Size by Application (2018-2023) & (USD Million)
Table 34. World Nucleotide-based Therapeutics Market Size by Application (2024-2029) & (USD Million)
Table 35. Sarepta Therapeutics Basic Information, Area Served and Competitors
Table 36. Sarepta Therapeutics Major Business
Table 37. Sarepta Therapeutics Nucleotide-based Therapeutics Product and Services
Table 38. Sarepta Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Sarepta Therapeutics Recent Developments/Updates
Table 40. Sarepta Therapeutics Competitive Strengths & Weaknesses
Table 41. Ionis Pharmaceuticals Basic Information, Area Served and Competitors
Table 42. Ionis Pharmaceuticals Major Business
Table 43. Ionis Pharmaceuticals Nucleotide-based Therapeutics Product and Services
Table 44. Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Ionis Pharmaceuticals Recent Developments/Updates
Table 46. Ionis Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Alnylam Basic Information, Area Served and Competitors
Table 48. Alnylam Major Business
Table 49. Alnylam Nucleotide-based Therapeutics Product and Services
Table 50. Alnylam Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Alnylam Recent Developments/Updates
Table 52. Alnylam Competitive Strengths & Weaknesses
Table 53. Biogen Basic Information, Area Served and Competitors
Table 54. Biogen Major Business
Table 55. Biogen Nucleotide-based Therapeutics Product and Services
Table 56. Biogen Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Biogen Recent Developments/Updates
Table 58. Biogen Competitive Strengths & Weaknesses
Table 59. Nippon Shinyaku Basic Information, Area Served and Competitors
Table 60. Nippon Shinyaku Major Business
Table 61. Nippon Shinyaku Nucleotide-based Therapeutics Product and Services
Table 62. Nippon Shinyaku Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Nippon Shinyaku Recent Developments/Updates
Table 64. Nippon Shinyaku Competitive Strengths & Weaknesses
Table 65. Sobi Basic Information, Area Served and Competitors
Table 66. Sobi Major Business
Table 67. Sobi Nucleotide-based Therapeutics Product and Services
Table 68. Sobi Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Sobi Recent Developments/Updates
Table 70. Sobi Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Area Served and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Nucleotide-based Therapeutics Product and Services
Table 74. Novartis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. BioNTech Basic Information, Area Served and Competitors
Table 78. BioNTech Major Business
Table 79. BioNTech Nucleotide-based Therapeutics Product and Services
Table 80. BioNTech Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. BioNTech Recent Developments/Updates
Table 82. BioNTech Competitive Strengths & Weaknesses
Table 83. Pfizer Basic Information, Area Served and Competitors
Table 84. Pfizer Major Business
Table 85. Pfizer Nucleotide-based Therapeutics Product and Services
Table 86. Pfizer Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Recent Developments/Updates
Table 88. Pfizer Competitive Strengths & Weaknesses
Table 89. Moderna Therapeutics Basic Information, Area Served and Competitors
Table 90. Moderna Therapeutics Major Business
Table 91. Moderna Therapeutics Nucleotide-based Therapeutics Product and Services
Table 92. Moderna Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Moderna Therapeutics Recent Developments/Updates
Table 94. Moderna Therapeutics Competitive Strengths & Weaknesses
Table 95. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
Table 96. Jazz Pharmaceuticals Major Business
Table 97. Jazz Pharmaceuticals Nucleotide-based Therapeutics Product and Services
Table 98. Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Jazz Pharmaceuticals Recent Developments/Updates
Table 100. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
Table 101. CureVac Basic Information, Area Served and Competitors
Table 102. CureVac Major Business
Table 103. CureVac Nucleotide-based Therapeutics Product and Services
Table 104. CureVac Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. CureVac Recent Developments/Updates
Table 106. CureVac Competitive Strengths & Weaknesses
Table 107. Regulus Therapeutics Basic Information, Area Served and Competitors
Table 108. Regulus Therapeutics Major Business
Table 109. Regulus Therapeutics Nucleotide-based Therapeutics Product and Services
Table 110. Regulus Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Regulus Therapeutics Recent Developments/Updates
Table 112. Regulus Therapeutics Competitive Strengths & Weaknesses
Table 113. ProQR Basic Information, Area Served and Competitors
Table 114. ProQR Major Business
Table 115. ProQR Nucleotide-based Therapeutics Product and Services
Table 116. ProQR Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. ProQR Recent Developments/Updates
Table 118. ProQR Competitive Strengths & Weaknesses
Table 119. Secarna Basic Information, Area Served and Competitors
Table 120. Secarna Major Business
Table 121. Secarna Nucleotide-based Therapeutics Product and Services
Table 122. Secarna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Secarna Recent Developments/Updates
Table 124. Secarna Competitive Strengths & Weaknesses
Table 125. MiNA Therapeutics Basic Information, Area Served and Competitors
Table 126. MiNA Therapeutics Major Business
Table 127. MiNA Therapeutics Nucleotide-based Therapeutics Product and Services
Table 128. MiNA Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. MiNA Therapeutics Recent Developments/Updates
Table 130. MiNA Therapeutics Competitive Strengths & Weaknesses
Table 131. Sylentis Basic Information, Area Served and Competitors
Table 132. Sylentis Major Business
Table 133. Sylentis Nucleotide-based Therapeutics Product and Services
Table 134. Sylentis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Sylentis Recent Developments/Updates
Table 136. Sylentis Competitive Strengths & Weaknesses
Table 137. Arrowhead Basic Information, Area Served and Competitors
Table 138. Arrowhead Major Business
Table 139. Arrowhead Nucleotide-based Therapeutics Product and Services
Table 140. Arrowhead Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Arrowhead Recent Developments/Updates
Table 142. Arrowhead Competitive Strengths & Weaknesses
Table 143. Silence Therapeutics Basic Information, Area Served and Competitors
Table 144. Silence Therapeutics Major Business
Table 145. Silence Therapeutics Nucleotide-based Therapeutics Product and Services
Table 146. Silence Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Silence Therapeutics Recent Developments/Updates
Table 148. Dicerna Basic Information, Area Served and Competitors
Table 149. Dicerna Major Business
Table 150. Dicerna Nucleotide-based Therapeutics Product and Services
Table 151. Dicerna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 152. Global Key Players of Nucleotide-based Therapeutics Upstream (Raw Materials)
Table 153. Nucleotide-based Therapeutics Typical Customers
LIST OF FIGURE
Figure 1. Nucleotide-based Therapeutics Picture
Figure 2. World Nucleotide-based Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Nucleotide-based Therapeutics Total Market Size (2018-2029) & (USD Million)
Figure 4. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 13. Nucleotide-based Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 16. World Nucleotide-based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. China Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 23. India Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Nucleotide-based Therapeutics by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Nucleotide-based Therapeutics Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Nucleotide-based Therapeutics Markets in 2022
Figure 27. United States VS China: Nucleotide-based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Nucleotide-based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Nucleotide-based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Nucleotide-based Therapeutics Market Size Market Share by Type in 2022
Figure 31. Antisense Oligonucleotides (ASO)
Figure 32. siRNA
Figure 33. mRNA
Figure 34. World Nucleotide-based Therapeutics Market Size Market Share by Type (2018-2029)
Figure 35. World Nucleotide-based Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Nucleotide-based Therapeutics Market Size Market Share by Application in 2022
Figure 37. Neuromuscular Diseases
Figure 38. hATTR
Figure 39. COVID-19
Figure 40. Other
Figure 41. Nucleotide-based Therapeutics Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
Table 1. World Nucleotide-based Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Nucleotide-based Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Nucleotide-based Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Nucleotide-based Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Nucleotide-based Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Nucleotide-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Nucleotide-based Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Nucleotide-based Therapeutics Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Nucleotide-based Therapeutics Players in 2022
Table 12. World Nucleotide-based Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Nucleotide-based Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Nucleotide-based Therapeutics Player
Table 15. Nucleotide-based Therapeutics Market: Company Product Type Footprint
Table 16. Nucleotide-based Therapeutics Market: Company Product Application Footprint
Table 17. Nucleotide-based Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Nucleotide-based Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Nucleotide-based Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)
Table 23. China Based Nucleotide-based Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)
Table 26. Rest of World Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)
Table 29. World Nucleotide-based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Nucleotide-based Therapeutics Market Size by Type (2018-2023) & (USD Million)
Table 31. World Nucleotide-based Therapeutics Market Size by Type (2024-2029) & (USD Million)
Table 32. World Nucleotide-based Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Nucleotide-based Therapeutics Market Size by Application (2018-2023) & (USD Million)
Table 34. World Nucleotide-based Therapeutics Market Size by Application (2024-2029) & (USD Million)
Table 35. Sarepta Therapeutics Basic Information, Area Served and Competitors
Table 36. Sarepta Therapeutics Major Business
Table 37. Sarepta Therapeutics Nucleotide-based Therapeutics Product and Services
Table 38. Sarepta Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Sarepta Therapeutics Recent Developments/Updates
Table 40. Sarepta Therapeutics Competitive Strengths & Weaknesses
Table 41. Ionis Pharmaceuticals Basic Information, Area Served and Competitors
Table 42. Ionis Pharmaceuticals Major Business
Table 43. Ionis Pharmaceuticals Nucleotide-based Therapeutics Product and Services
Table 44. Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Ionis Pharmaceuticals Recent Developments/Updates
Table 46. Ionis Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Alnylam Basic Information, Area Served and Competitors
Table 48. Alnylam Major Business
Table 49. Alnylam Nucleotide-based Therapeutics Product and Services
Table 50. Alnylam Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Alnylam Recent Developments/Updates
Table 52. Alnylam Competitive Strengths & Weaknesses
Table 53. Biogen Basic Information, Area Served and Competitors
Table 54. Biogen Major Business
Table 55. Biogen Nucleotide-based Therapeutics Product and Services
Table 56. Biogen Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Biogen Recent Developments/Updates
Table 58. Biogen Competitive Strengths & Weaknesses
Table 59. Nippon Shinyaku Basic Information, Area Served and Competitors
Table 60. Nippon Shinyaku Major Business
Table 61. Nippon Shinyaku Nucleotide-based Therapeutics Product and Services
Table 62. Nippon Shinyaku Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Nippon Shinyaku Recent Developments/Updates
Table 64. Nippon Shinyaku Competitive Strengths & Weaknesses
Table 65. Sobi Basic Information, Area Served and Competitors
Table 66. Sobi Major Business
Table 67. Sobi Nucleotide-based Therapeutics Product and Services
Table 68. Sobi Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Sobi Recent Developments/Updates
Table 70. Sobi Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Area Served and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Nucleotide-based Therapeutics Product and Services
Table 74. Novartis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. BioNTech Basic Information, Area Served and Competitors
Table 78. BioNTech Major Business
Table 79. BioNTech Nucleotide-based Therapeutics Product and Services
Table 80. BioNTech Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. BioNTech Recent Developments/Updates
Table 82. BioNTech Competitive Strengths & Weaknesses
Table 83. Pfizer Basic Information, Area Served and Competitors
Table 84. Pfizer Major Business
Table 85. Pfizer Nucleotide-based Therapeutics Product and Services
Table 86. Pfizer Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Recent Developments/Updates
Table 88. Pfizer Competitive Strengths & Weaknesses
Table 89. Moderna Therapeutics Basic Information, Area Served and Competitors
Table 90. Moderna Therapeutics Major Business
Table 91. Moderna Therapeutics Nucleotide-based Therapeutics Product and Services
Table 92. Moderna Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Moderna Therapeutics Recent Developments/Updates
Table 94. Moderna Therapeutics Competitive Strengths & Weaknesses
Table 95. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
Table 96. Jazz Pharmaceuticals Major Business
Table 97. Jazz Pharmaceuticals Nucleotide-based Therapeutics Product and Services
Table 98. Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Jazz Pharmaceuticals Recent Developments/Updates
Table 100. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
Table 101. CureVac Basic Information, Area Served and Competitors
Table 102. CureVac Major Business
Table 103. CureVac Nucleotide-based Therapeutics Product and Services
Table 104. CureVac Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. CureVac Recent Developments/Updates
Table 106. CureVac Competitive Strengths & Weaknesses
Table 107. Regulus Therapeutics Basic Information, Area Served and Competitors
Table 108. Regulus Therapeutics Major Business
Table 109. Regulus Therapeutics Nucleotide-based Therapeutics Product and Services
Table 110. Regulus Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Regulus Therapeutics Recent Developments/Updates
Table 112. Regulus Therapeutics Competitive Strengths & Weaknesses
Table 113. ProQR Basic Information, Area Served and Competitors
Table 114. ProQR Major Business
Table 115. ProQR Nucleotide-based Therapeutics Product and Services
Table 116. ProQR Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. ProQR Recent Developments/Updates
Table 118. ProQR Competitive Strengths & Weaknesses
Table 119. Secarna Basic Information, Area Served and Competitors
Table 120. Secarna Major Business
Table 121. Secarna Nucleotide-based Therapeutics Product and Services
Table 122. Secarna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Secarna Recent Developments/Updates
Table 124. Secarna Competitive Strengths & Weaknesses
Table 125. MiNA Therapeutics Basic Information, Area Served and Competitors
Table 126. MiNA Therapeutics Major Business
Table 127. MiNA Therapeutics Nucleotide-based Therapeutics Product and Services
Table 128. MiNA Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. MiNA Therapeutics Recent Developments/Updates
Table 130. MiNA Therapeutics Competitive Strengths & Weaknesses
Table 131. Sylentis Basic Information, Area Served and Competitors
Table 132. Sylentis Major Business
Table 133. Sylentis Nucleotide-based Therapeutics Product and Services
Table 134. Sylentis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Sylentis Recent Developments/Updates
Table 136. Sylentis Competitive Strengths & Weaknesses
Table 137. Arrowhead Basic Information, Area Served and Competitors
Table 138. Arrowhead Major Business
Table 139. Arrowhead Nucleotide-based Therapeutics Product and Services
Table 140. Arrowhead Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Arrowhead Recent Developments/Updates
Table 142. Arrowhead Competitive Strengths & Weaknesses
Table 143. Silence Therapeutics Basic Information, Area Served and Competitors
Table 144. Silence Therapeutics Major Business
Table 145. Silence Therapeutics Nucleotide-based Therapeutics Product and Services
Table 146. Silence Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Silence Therapeutics Recent Developments/Updates
Table 148. Dicerna Basic Information, Area Served and Competitors
Table 149. Dicerna Major Business
Table 150. Dicerna Nucleotide-based Therapeutics Product and Services
Table 151. Dicerna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 152. Global Key Players of Nucleotide-based Therapeutics Upstream (Raw Materials)
Table 153. Nucleotide-based Therapeutics Typical Customers
LIST OF FIGURE
Figure 1. Nucleotide-based Therapeutics Picture
Figure 2. World Nucleotide-based Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Nucleotide-based Therapeutics Total Market Size (2018-2029) & (USD Million)
Figure 4. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
Figure 13. Nucleotide-based Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 16. World Nucleotide-based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. China Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 23. India Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Nucleotide-based Therapeutics by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Nucleotide-based Therapeutics Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Nucleotide-based Therapeutics Markets in 2022
Figure 27. United States VS China: Nucleotide-based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Nucleotide-based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Nucleotide-based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Nucleotide-based Therapeutics Market Size Market Share by Type in 2022
Figure 31. Antisense Oligonucleotides (ASO)
Figure 32. siRNA
Figure 33. mRNA
Figure 34. World Nucleotide-based Therapeutics Market Size Market Share by Type (2018-2029)
Figure 35. World Nucleotide-based Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Nucleotide-based Therapeutics Market Size Market Share by Application in 2022
Figure 37. Neuromuscular Diseases
Figure 38. hATTR
Figure 39. COVID-19
Figure 40. Other
Figure 41. Nucleotide-based Therapeutics Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
